Lilly Announced Saturday, SURMOUNT-2 Results Published In The Lancet Show Tirzepatide Achieved A Mean Weight Reduction Of 15.7% At The Highest Dose (15 Mg) In Adults With Obesity Or Overweight And Type 2 Diabetes
Portfolio Pulse from Charles Gross
Eli Lilly announced that its SURMOUNT-2 study results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes.
June 26, 2023 | 11:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's tirzepatide showed promising results in the SURMOUNT-2 study, achieving a 15.7% mean weight reduction in adults with obesity and type 2 diabetes.
The positive results from the SURMOUNT-2 study indicate that tirzepatide has the potential to be an effective treatment for obesity and type 2 diabetes. This could lead to increased demand for the drug and potentially boost Eli Lilly's revenues and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100